162 related articles for article (PubMed ID: 26807543)
1. Galactose conjugated platinum(II) complex targeting the Warburg effect for treatment of non-small cell lung cancer and colon cancer.
Wu M; Li H; Liu R; Gao X; Zhang M; Liu P; Fu Z; Yang J; Zhang-Negrerie D; Gao Q
Eur J Med Chem; 2016 Mar; 110():32-42. PubMed ID: 26807543
[TBL] [Abstract][Full Text] [Related]
2. Highly water-soluble platinum(II) complexes as GLUT substrates for targeted therapy: improved anticancer efficacy and transporter-mediated cytotoxic properties.
Liu P; Lu Y; Gao X; Liu R; Zhang-Negrerie D; Shi Y; Wang Y; Wang S; Gao Q
Chem Commun (Camb); 2013 Mar; 49(24):2421-3. PubMed ID: 23420130
[TBL] [Abstract][Full Text] [Related]
3. Synthesis of antitumor azolato-bridged dinuclear platinum(ii) complexes with in vivo antitumor efficacy and unique in vitro cytotoxicity profiles.
Komeda S; Takayama H; Suzuki T; Odani A; Yamori T; Chikuma M
Metallomics; 2013 May; 5(5):461-8. PubMed ID: 23608770
[TBL] [Abstract][Full Text] [Related]
4. A novel cyclometallated Pt(II)-ferrocene complex induces nuclear FOXO3a localization and apoptosis and synergizes with cisplatin to inhibit lung cancer cell proliferation.
Cortés R; Tarrado-Castellarnau M; Talancón D; López C; Link W; Ruiz D; Centelles JJ; Quirante J; Cascante M
Metallomics; 2014 Mar; 6(3):622-33. PubMed ID: 24492855
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of a new platinum(II) complex with low nephrotoxicity and genotoxicity.
Marzano C; Bettio F; Baccichetti F; Trevisan A; Giovagnini L; Fregona D
Chem Biol Interact; 2004 Jun; 148(1-2):37-48. PubMed ID: 15223355
[TBL] [Abstract][Full Text] [Related]
6. Characterizations of irofulven cytotoxicity in combination with cisplatin and oxaliplatin in human colon, breast, and ovarian cancer cells.
Serova M; Calvo F; Lokiec F; Koeppel F; Poindessous V; Larsen AK; Laar ES; Waters SJ; Cvitkovic E; Raymond E
Cancer Chemother Pharmacol; 2006 Apr; 57(4):491-9. PubMed ID: 16075278
[TBL] [Abstract][Full Text] [Related]
7. Chemosensitization and radiosensitization of human lung and colon cancers by antimitotic agent, ABT-751, in athymic murine xenograft models of subcutaneous tumor growth.
Jorgensen TJ; Tian H; Joseph IB; Menon K; Frost D
Cancer Chemother Pharmacol; 2007 May; 59(6):725-32. PubMed ID: 16967299
[TBL] [Abstract][Full Text] [Related]
8. Preclinical efficacy and pharmacokinetics of AP5346, a novel diaminocyclohexane-platinum tumor-targeting drug delivery system.
Rice JR; Gerberich JL; Nowotnik DP; Howell SB
Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2248-54. PubMed ID: 16609041
[TBL] [Abstract][Full Text] [Related]
9. Platinum-acridinylthiourea conjugates show cell line-specific cytotoxic enhancement in H460 lung carcinoma cells compared to cisplatin.
Hess SM; Mounce AM; Sequeira RC; Augustus TM; Ackley MC; Bierbach U
Cancer Chemother Pharmacol; 2005 Oct; 56(4):337-43. PubMed ID: 15895232
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers.
Raymond E; Buquet-Fagot C; Djelloul S; Mester J; Cvitkovic E; Allain P; Louvet C; Gespach C
Anticancer Drugs; 1997 Oct; 8(9):876-85. PubMed ID: 9402315
[TBL] [Abstract][Full Text] [Related]
11. In vitro studies on the mechanisms of oxaliplatin resistance.
Hector S; Bolanowska-Higdon W; Zdanowicz J; Hitt S; Pendyala L
Cancer Chemother Pharmacol; 2001 Nov; 48(5):398-406. PubMed ID: 11761458
[TBL] [Abstract][Full Text] [Related]
12. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
13. The sirtuin inhibitor tenovin-6 upregulates death receptor 5 and enhances cytotoxic effects of 5-fluorouracil and oxaliplatin in colon cancer cells.
Ueno T; Endo S; Saito R; Hirose M; Hirai S; Suzuki H; Yamato K; Hyodo I
Oncol Res; 2013; 21(3):155-64. PubMed ID: 24512730
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxicity, cellular uptake, and cellular biotransformations of oxaliplatin in human colon carcinoma cells.
Luo FR; Wyrick SD; Chaney SG
Oncol Res; 1998; 10(11-12):595-603. PubMed ID: 10367941
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic and pharmacodynamic analysis of bis-acetato-ammine-dichloro-cyclohexylamine-platinum(IV) (JM216) administered once a day for five consecutive days: a phase I study.
Kurata T; Tamura T; Sasaki Y; Fujii H; Negoro S; Fukuoka M; Saijo N
Jpn J Clin Oncol; 2000 Sep; 30(9):377-84. PubMed ID: 11095134
[TBL] [Abstract][Full Text] [Related]
16. Oroxylin A sensitizes non-small cell lung cancer cells to anoikis via glucose-deprivation-like mechanisms: c-Src and hexokinase II.
Wei L; Dai Q; Zhou Y; Zou M; Li Z; Lu N; Guo Q
Biochim Biophys Acta; 2013 Jun; 1830(6):3835-45. PubMed ID: 23500080
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, characterization, and biological evaluation of new tetrazole-based platinum(II) and palladium(II) chlorido complexes--potent cisplatin analogues and their trans isomers.
Serebryanskaya TV; Yung T; Bogdanov AA; Shchebet A; Johnsen SA; Lyakhov AS; Ivashkevich LS; Ibrahimava ZA; Garbuzenco TS; Kolesnikova TS; Melnova NI; Gaponik PN; Ivashkevich OA
J Inorg Biochem; 2013 Mar; 120():44-53. PubMed ID: 23305964
[TBL] [Abstract][Full Text] [Related]
18. Anticancer activity in murine and human tumor cell lines of bis(platinum) complexes incorporating straight-chain aliphatic diamine linker groups.
Kraker AJ; Hoeschele JD; Elliott WL; Showalter HD; Sercel AD; Farrell NP
J Med Chem; 1992 Nov; 35(24):4526-32. PubMed ID: 1335074
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of novel platinum complexes, inhibitors of topoisomerase I and II in non-small cell lung cancer (NSCLC) sublines resistant to cisplatin.
Fukuda M; Ohe Y; Kanzawa F; Oka M; Hara K; Saijo N
Anticancer Res; 1995; 15(2):393-8. PubMed ID: 7763011
[TBL] [Abstract][Full Text] [Related]
20. Reduced drug accumulation is more important in acquired resistance against oxaliplatin than against cisplatin in isogenic colon cancer cells.
Ekblad L; Kjellström J; Johnsson A
Anticancer Drugs; 2010 Jun; 21(5):523-31. PubMed ID: 20168208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
